Iovance Biotherapeutics (IOVA) Q2 2026 earnings review
Record Sales and Surging Margins Show Clear Path to Profitability
Iovance delivered a breakout quarter. Total revenue accelerated 66% YoY to $99.3M, driven by surging U.S. Amtagvi demand following network expansion and a new marketing campaign. More importantly, operational leverage is finally kicking in: gross margin hit a record 56% (up from 41% in Q1), and a fourth consecutive quarter of R&D cuts helped shrink the net loss to $47.3M—less than half of the $111.7M loss reported a year ago. The momentum is so strong that management is reviewing its FY26 guidance of $350-370M for a likely upward revision.
🐂 Bull Case
Gross margin expanded to 56%, reversing the Q1 dip (41%) caused by facility maintenance. Centralized manufacturing is generating real economies of scale.
Despite a 66% YoY surge in revenue, total R&D and SG&A expenses dropped 15% YoY ($98M vs $115M), extending the cash runway to 2H28.
🐻 Bear Case
The European (EMA) marketing application is delayed to 2027, and the UK MAA was withdrawn and just recently resubmitted, pushing significant ex-U.S. revenue further out.
Proleukin sales dropped sequentially to $9M from $11M in Q1, despite Amtagvi sales surging 51% QoQ, contradicting management's thesis that the companion drug would track Amtagvi growth.
⚖️ Verdict: 🟢🟢
Bullish. The company is proving it can commercialize complex cell therapies at scale while rigorously controlling costs. The combination of accelerating revenue and shrinking losses de-risks the financial profile.
Key Themes
Amtagvi Commercial Acceleration
U.S. Amtagvi demand is accelerating, with Q2 revenue of ~$91M representing a massive 51% sequential jump from Q1's $60M. The Authorized Treatment Center (ATC) network has grown to over 95 sites. Crucially, community ATCs now represent a third of the network, successfully bridging the gap between specialized academic centers and broader patient access. Unaided physician awareness has nearly tripled over the last year.
Manufacturing Scale Driving Margin Upward
Gross margin reached a record 56% (excluding depreciation and amortization), bouncing back aggressively from the 41% reported in Q1 (which was depressed by facility maintenance). This validates management's strategy to internalize all manufacturing at the iCTC facility. As volume increases, fixed costs are better absorbed, setting up a clear trajectory toward software-like margins in the long term.
Proleukin Revenue Disconnect
A clear data contradiction emerged this quarter: management previously guided that Proleukin (IL-2) sales would scale alongside Amtagvi adoption. However, while Amtagvi revenue surged 51% QoQ (from $60M to $91M), Proleukin revenue actually declined 18% QoQ (from $11M to $9M) and is down sharply from its $22M peak in 25Q4. This suggests either heavy wholesaler inventory manipulation or alternative IL-2 sourcing by treatment centers.
Pipeline: Expanding Beyond Melanoma
The company continues to advance registrational programs in markets much larger than melanoma. The IOV-LUN-202 trial for NSCLC (a market 7x larger than melanoma) is nearing enrollment completion for pivotal cohorts, with updates slated for 4Q26. Additionally, the FDA granted Fast Track Designation for lifileucel in soft tissue sarcomas (SARATOGA trial), riding on early data showing a 50% objective response rate.
International Execution Delays
The timeline for European revenue continues to slip. The EMA resubmission is now explicitly targeted for 2027 (originally expected much earlier before the 25Q2 withdrawal). The UK MAA was also withdrawn in May 2026 for procedural reasons and only recently resubmitted. Aside from Australia and Canada, Iovance is highly exposed to single-market risk in the U.S.
Other KPIs
Decreasing. This marks the fourth straight quarter of operational improvements, down 6% sequentially from Q1 2026 and down 24% YoY from $77.9M in Q2 2025. This discipline is the primary reason the company's cash runway now stretches into the second half of 2028.
Stable. The company ended Q2 with ~$304 million in cash and short-term investments, down only slightly from Q1's ~$319 million. With net losses shrinking rapidly (down to $47.3M this quarter), the prior reliance on the ATM facility should diminish.
Guidance
Accelerating. Based on the $99.3M Q2 beat and strong demand trends, management is reviewing this prior guidance range and plans to provide an update in Q3. Reaching just the midpoint ($360M) requires ~$190M in the second half, a hurdle that now looks conservative given the Q2 exit rate.
Key Questions
Proleukin Ordering Dynamics
Why did Proleukin revenue decline sequentially in a quarter where Amtagvi infusions clearly surged? Are ATCs utilizing alternate IL-2 supplies, or is this purely wholesaler inventory burn?
Gross Margin Ceiling
With gross margin jumping to 56% this quarter, what is the theoretical ceiling for margins as the iCTC facility approaches full capacity utilization?
Ex-U.S. Capital Requirements
As you prepare for potential UK and Australian approvals while pushing the EMA resubmission to 2027, what are the anticipated SG&A build-out costs to launch in these regions without a partner?